CJC-1295 made a hormone signal last.
A clever way to stay in the blood caught my eye. Any claim about daily life still needs its own evidence.
The small label detail that matters.
CJC-1295 is built on a piece of the brain hormone called growth hormone-releasing hormone. It sends the pituitary gland a message to release growth hormone.
The form called DAC has an extra chemical hook. It attaches to albumin, a common blood protein, helping it stay around for days. That’s the form behind the published human hormone results.
A version without DAC is also discussed online. FDA’s review of the different forms identifies two different active ingredients. FDA couldn’t find studies testing the version without DAC in people. A few letters on a label change which evidence belongs with it.
Once the form is clear, we can look at what researchers actually measured.
The rise was in blood measurements.
In small studies of healthy adults, growth hormone and IGF-1 stayed raised for days with the DAC form. IGF-1 is a growth factor whose production growth hormone helps drive. The result shows that the molecule kept the hormone message going. It doesn’t tell us what that meant for an ordinary day.
FDA’s review found that the published human studies hadn’t measured benefits such as better sleep, fat loss or greater strength. If one of those brought you here, the gap matters. I can follow the chemistry and still be left waiting for an answer about the thing you actually care about.
A longer signal also leaves an important question about safety.
Withdrawal wasn’t a safety clearance.
FDA’s safety page puts CJC-1295 under nominated but withdrawn. That means the request for its consideration in compounding was taken back.
Its content-current stamp reads April 22, 2026. That’s a page date, with no date given for this substance’s withdrawal. Withdrawal doesn’t mean clearance or placement in Category 1.
The same entry still carries safety concerns, including serious reports of faster heart rate and flushing-type reactions. FDA also discusses low blood pressure and the possibility of an immune reaction. Long-term human safety is unknown. There’s no FDA-approved CJC-1295 medicine or current drug label to fill those gaps.
The access page explains why a withdrawn request doesn’t create a prescribing route.
The hook explains the duration.
It can’t supply the missing health result. The comparison with sermorelin and tesamorelin keeps the different kinds of finding in view, without picking a winner from a hormone graph.